Abstract 145P
Background
Implementation of preoperative CRT in patients (pts) with locally advanced R-ESCC is suboptimal for many reasons, including safety concerns. PET/CT scanning has shown positive predictive data and may help optimize neoadjuvant treatment in R-ESCC. We report the primary analysis of an ongoing, phase 2, multicenter study conducted in China, which investigated the efficacy and safety of PET/CT-guided neoadjuvant treatment with TIS, an anti-programmed cell death protein 1 antibody, plus Chemo/CRT in R-ESCC (NCT04974047).
Methods
Therapy-naïve adult pts with AJCC 8th Ed. Stage cT1-2N+M0 or cT3NanyM0 R-ESCC received a PET/CT scan at baseline (BL), then one cycle of induction Chemo (cisplatin-paclitaxel [Cis-Pac]), and another PET/CT scan 15-21 days later. Pts were categorized into two cohorts per response to induction Chemo, based on the decrease from BL in PET maximum standardized uptake value in the primary tumor (responders [R]: ≥35%, nonresponders [NR]: <35%). Both cohorts received three cycles of TIS 200 mg IV + two cycles of Chemo (Cis-Pac) Q3W for R or two cycles of CRT (investigator-chosen Cis-Pac or Cis-5-FU + radiotherapy [40 Grays in 20 fractions]) for NR. Pts then underwent surgery. The primary endpoint was postresection pathological complete response (pCR) rate; secondary endpoints included R0 resection rate and safety (adverse events [AEs]).
Results
Of 70 pts enrolled, 15 (21%) and 48 (69%) had stage II and III disease at BL, respectively. Thirty pts were R and 40 were NR to induction Chemo. Of the R, 21 (70%) had undergone surgery; the pCR rate was 29% (n=6; 95% CI: 11, 52); the R0 resection rate was 95%. Of the NR, 33 (83%) had undergone surgery; the pCR rate was 33% (n=11; 95% CI: 18, 52); the R0 resection rate was 91%. Fourteen pts (47%) in the R cohort and 33 pts (83%) in the NR cohort had ≥grade 3 treatment-related AEs (TRAEs); AEs leading to treatment discontinuation occurred in one pt (3%) and four pts (10%), respectively. No pts had surgery canceled due to AEs. No TRAEs leading to death were reported.
Conclusions
As neoadjuvant treatment in pts with R-ESCC, TIS + Chemo/CRT demonstrated promising pCR rates and tolerable safety in both R and NR (PET/CT-assessed).
Clinical trial identification
NCT04974047, first posted July 23, 2021.
Editorial acknowledgement
This study was sponsored by BeiGene, Ltd. Medical writing support, under direction of the authors, was provided by Ghina Yaacoub, MSc, of Ashfield MedComms, an Inizio company, and was funded by BeiGene, Ltd.
Legal entity responsible for the study
BeiGene, Ltd.
Funding
BeiGene, Ltd.
Disclosure
L. Chen, Y. Liao, T. Jiang, M. Kang, X. Mei, L. Tan, J. Liu, H. Jiang: Non-Financial Interests, Institutional, Principal Investigator: BeiGene. Z. Zhang, W. Yu: Financial Interests, Personal, Full or part-time Employment: BeiGene. L. Li: Financial Interests, Personal, Full or part-time Employment: BeiGene (Beijing) Co., Ltd; Financial Interests, Personal, Stocks/Shares: BeiGene (Beijing) Co., Ltd; Financial Interests, Personal, Training: BeiGene (Beijing) Co., Ltd.
Resources from the same session
540P - Phase III study of serplulimab plus chemotherapy as first-line therapy for advanced squamous non-small cell lung cancer: ASTRUM-004 Asian subgroup
Presenter: Caicun Zhou
Session: Poster Display
Resources:
Abstract
541P - Integrated analysis of randomized controlled trials IMpower130 and IMpower132 for advanced non-squamous non-small cell lung cancer (NSCLC)
Presenter: Hibiki Udagawa
Session: Poster Display
Resources:
Abstract
542P - First-line HLX07 plus serplulimab with or without chemotherapy versus serplulimab plus chemotherapy in advanced/recurrent squamous non-small cell lung cancer: A phase II study
Presenter: Zhen Wang
Session: Poster Display
Resources:
Abstract
543P - A multicenter retrospective study to investigate risk factors for immune checkpoint inhibitor-induced pneumonitis in non-small cell lung cancer patients with comorbid interstitial pneumonia
Presenter: Yuriko Ishida
Session: Poster Display
Resources:
Abstract
544P - Single cell level investigation of blood cells representing immune checkpoint inhibitor response in lung adenocarcinoma patients
Presenter: Juyong Seong
Session: Poster Display
Resources:
Abstract
545P - Completion of pembrolizumab in advanced non-small cell lung cancer: Real-world outcomes after two years of therapy (COPILOT)
Presenter: Andrew Fantoni
Session: Poster Display
Resources:
Abstract
546P - Combination therapy with anti-PD-1 antibody plus angiokinase inhibitor exerts synergistic antitumor effect against malignant mesothelioma via tumor microenvironment modulation
Presenter: Akio Tada
Session: Poster Display
Resources:
Abstract
547P - Immunotherapy outcome in advanced/metastatic lung cancer patients in real-world experience: Indian data
Presenter: Naveen K
Session: Poster Display
Resources:
Abstract
548P - B-Myb acts as a mentor instant promoter in non-small cell lung cancer by modifying the PD-1/PD-L1 axis
Presenter: Pan Xu
Session: Poster Display
Resources:
Abstract
549P - Drug-induced interstitial lung disease in patients with non-small cell lung cancer treated with immunotherapy for postoperative recurrence: Evaluation of CT findings and histopathological findings of the background lung
Presenter: shodai fujimoto
Session: Poster Display
Resources:
Abstract